Organoid Scientific Research Service

A personalized testing service using patient-derived organoids to evaluate drug efficacy and identify optimal therapeutic candidates for individual cancer treatment protocols.

A clinical service that provides personalized treatment planning using patient-derived 3D cell culture models. The service leverages cultured patient cells to enable precision medicine approaches in cancer care. It supports clinicians in making informed treatment decisions based on individual patient cell behavior.

Design and manufacturing of specialized organ chip configurations for specific tissue types or research questions. Includes model validation and performance characterization.

Customized organ chip design and manufacturing service tailored to specific research or pharmaceutical development requirements. Includes model validation and optimization support.

Comprehensive pharmaceutical development service utilizing organ chip platforms for preclinical efficacy and toxicity assessment. Covers early discovery through clinical trial preparation phases.

Custom computational service automating anatomical structure extraction from medical imaging. Available for medical device manufacturers, researchers and clinicians requiring automated segmentation of distinct anatomical structures from diagnostic imaging data.

Service for automated conversion of medical imaging data to 3D anatomical models suitable for surgical planning and visualization. Supports rapid model generation from patient scans.

Specialized sequencing service for single-cell and spatial omics research applications. Provides high-resolution genomic analysis of individual cells and tissue spatial organization.

A professional service providing three-dimensional anatomical reconstruction and preoperative surgical planning based on patient imaging data for clinical applications.

Three-dimensional organoid culture development from patient tumor samples for personalized drug testing. This approach preserves tumor heterogeneity and enables functional assessment of therapeutic responses.

Patient-derived cell model development service for preclinical drug evaluation and tumor biology studies. This service provides authentic cellular models that retain primary tumor characteristics for improved drug testing accuracy.

Development of patient-derived tumor organoids for therapeutic efficacy testing and precision medicine applications with accurate replication of tumor characteristics.